Objectives: Options for treatment of infections due to KPC-producing Klebsiella pneumoniae are limited and combination therapy is often recommended. In this report, the in vitro and in vivo activity of potential therapeutic agents and combinations was assessed against four KPC-producing K. pneumoniae isolates.
Introduction
The global spread of pathogens harbouring KPC over the past two decades has been relentless. 1 Infections with these bacteria are associated with high mortality rates. 2, 3 Therapeutic options are extremely limited and often a polymyxin is the backbone of a therapeutic regimen. Additional agents, such as a carbapenem, rifampicin or tigecycline, may result in enhanced activity. [4] [5] [6] Combination therapy is generally recommended and may be associated with improved clinical outcomes, particularly for bacteraemic patients. 3, [7] [8] [9] The development of new b-lactamase inhibitors, including the diazabicyclooctane inhibitors avibactam and relebactam and the boronate inhibitor vaborbactam, offers new therapeutic options. 10 The combination of ceftazidime/avibactam has demonstrated in vitro activity against a wide range of Gram-negative pathogens, including those harbouring bla KPC . 11 However, KPC-producing Klebsiella pneumoniae isolates resistant to ceftazidime/avibactam have been reported, including isolates with emergence of resistance following exposure to this agent. 12, 13 In this report, we examined the activity of ceftazidime/avibactam and polymyxin B, alone and combined with other agents, against four KPC-producing K. pneumoniae isolates. Time-kill experiments to examine the in vitro activity of several potential therapeutic options were performed. In addition, the in vivo activity of these agents was assessed using the Galleria mellonella model of infection. 14, 15 
Materials and methods
In vitro studies Four KPC-producing K. pneumoniae clinical isolates were studied. The isolates were chosen because they had varying KPC alleles and MICs of polymyxin B and/or ceftazidime/avibactam. MICs and time-kill studies were performed in cation-supplemented Mueller-Hinton broth, as previously described. 16 For the time-kill studies the following antibiotic concentrations, chosen to represent clinically relevant levels, were used: 2 mg/L polymyxin B; 4/4 mg/L ceftazidime/avibactam; 4 mg/L meropenem; 16 mg/L amikacin; and 1 mg/L rifampicin. In addition to each antibiotic alone, the following combinations were tested: ceftazidime/avibactam with amikacin, ceftazidime/avibactam with meropenem, ceftazidime/avibactam with polymyxin B, polymyxin B with meropenem and polymyxin B with rifampicin. Time-kill experiments were also performed using ceftazidime/avibactam concentrations at one-quarter of the MIC of ceftazidime/avibactam. The lowest limit of detection was 10 cfu/mL. Bactericidal activity was defined as a 1000-fold decrease in the log 10 cfu/mL at 24 h. Synergy was defined as a 100-fold decrease in the log 10 cfu/mL at 24 h in the combination compared with either antibiotic alone. Antagonism was defined as 100-fold reduced killing with the combination therapy when compared with either of the single agents.
Fingerprinting was performed using the repPCR method with ERIC-2 primers, as previously described. 17 The presence of bla KPC was confirmed and identified using previously reported primers and PCR conditions. 4 The porin genes ompK35 and ompK36 were amplified and sequenced, as previously described. 18 G. mellonella killing studies G. mellonella caterpillars were stored at 4 C prior to use. Caterpillars were selected weighing 150-200 mg each. Caterpillars were inoculated with 10 lL of K. pneumoniae at a concentration of 5%10 8 cfu/mL prepared in PBS. This inoculum was required to kill most caterpillars over a 1-2 day period. A minimum of 20 caterpillars were in each treatment group; they were kept in Petri dishes at room temperature and inspected daily for 6 days. Survival rates were recorded for each day; statistical analyses were performed for the rates on days 1, 3 and 6.
The following antibiotics, obtained from vials for clinical use, were administered to infected caterpillars: polymyxin B, ceftazidime/avibactam, meropenem, amikacin and rifampicin. To ensure clinically relevant levels, antibiotic concentrations in the haemolymph of caterpillars were determined 4 h after administration. Bioassays were performed using the following bacteria: Escherichia coli ATCC 25922 (for ceftazidime/avibactam, meropenem and amikacin), Staphylococcus aureus ATCC 29213 (for rifampicin) and a clinical isolate of Bordetella bronchiseptica (for polymyxin B). 19 The selected doses, and the corresponding 4 h concentrations, were: 9 lg/mg polymyxin B (levels 1.7+0.92 mg/L); 8 lg/mg meropenem (levels 22.6+6.8 mg/L); 30 mg/g amikacin (levels 31.2+11.6 mg/L); and 0.625 lg/mg rifampicin (levels 0.95+0.17 mg/L). For ceftazidime/avibactam, two different doses were used: 21 mg/g of the ceftazidime component (yielding 4 h levels of 32.8+7.5 mg/L) and 2.6 mg/g (yielding 4 h levels of 6.3+1.4 mg/L). The two concentrations of ceftazidime/avibactam were chosen to reflect human level midway and at the end of a dosing interval. In addition to each antibiotic alone, the following combinations were tested: polymyxin B with meropenem, polymyxin B with rifampicin and low-dose ceftazidime/avibactam with polymyxin B, amikacin or meropenem. Antibiotics were diluted in PBS and the final volume for all injections was 10 lL. A single dose of antibiotics was given 30 min after inoculation with K. pneumoniae; controls were administered PBS following inoculation.
Fisher's exact test was used to determine significant differences in survival rates. Two-tailed P 0.05 was considered significant.
Results

Isolate ME9
Isolate ME9 was resistant to polymyxin B, meropenem and amikacin, and the ceftazidime/avibactam MIC was 8/4 mg/L ( Table 1) . This isolate possessed a frameshift mutation at amino acid 42 in ompK35 and an IS4 after amino acid 32 in ompK36. At the concentrations used, none of the antibiotics, either singly or in combination, resulted in bactericidal activity in the time-kill studies ( Figure 1a ). Ceftazidime/avibactam by itself resulted in an increase of 1 log 10 cfu/mL at 24 h. Synergistic inhibition was present with the combinations of ceftazidime/avibactam with amikacin and ceftazidime/avibactam with meropenem. However, synergy was not observed for these combinations when concentrations of ceftazidime/avibactam at one-quarter of the MIC were used. More than 3 log growth occurred in the presence of polymyxin B with either meropenem or rifampicin (data not shown).
In the G. mellonella model of infection, single drug therapy with meropenem (P " 0.01) and the lower dose of ceftazidime/avibactam (P 0.001) improved survival rates at day 6 only ( Figure 2a ); however, the survival rate hovered around 50%. Survival was significantly (P 0.006) greater in the treatment group receiving the higher dose of ceftazidime/avibactam at days 1, 3 and 6. When combined with the lower dose of ceftazidime/avibactam, improved survival was observed with polymyxin B on day 1 (P " 0.01) and with amikacin on day 6 (P " 0.03). When lower dose ceftazidime/avibactam was combined with meropenem, significantly higher survival rates were observed at 1, 3 and 6 days (P 0.001 for all 3 days) than either agent alone. For this isolate, treatment with the combinations of polymyxin B with rifampicin or meropenem were not significantly improved when compared with corresponding single agent therapy; at day 3, mortality was actually higher in the group that received polymyxin B and meropenem than the group that received meropenem alone (P " 0.0009).
Isolate IF19
Isolate IF19 was also resistant to polymyxin, meropenem and amikacin, and had a ceftazidime/avibactam MIC of 8/4 mg/L ( Table 1 ). This isolate had the same repPCR pattern as isolate ME9, but a different KPC allele. The identical frameshift mutation was detected in ompK35, but a transposase IS was found after amino acid 14 in ompK36. For the time-kill studies, growth was observed when antibiotics were used singly ( Figure 1b ). Ceftazidime/ Nath et al.
avibactam resulted in an increase of 1.5 log 10 cfu/mL at 24 h. Synergistic and bactericidal activity was observed with the combinations of ceftazidime/avibactam with amikacin, meropenem or polymyxin B. Using a concentration of one-quarter of the MIC of ceftazidime/avibactam, synergistic and bactericidal activity was maintained when it was combined with meropenem and polymyxin B, but not amikacin. For the polymyxin B-based regimens, synergistic bactericidal activity was observed with the combination of polymyxin B and rifampicin, but not with meropenem. Isolate IF19 appeared to be the most virulent of the four isolates, with nearly all control G. mellonella dead by day 3 (Figure 2b ). For the monotherapy groups, improved survival was seen following administration of polymyxin B on day 1 (P " 0.01) and meropenem on days 1 and 3 (P 0.001). Treatment with ceftazidime/avibactam resulted in significantly improved survival. At day 3, both low-and high-dose therapy resulted in improved survival (P 0.001). Improved survival was also seen on day 6 for both the low-dose (P " 0.01) and high-dose (P " 0.0002) ceftazidime/avibactam treatment groups. When compared with single drug therapy, improved survival was seen for the combination therapy of low-dose ceftazidime/avibactam with polymyxin B on day 1 (P " 0.05), amikacin on days 1 and 6 (P " 0.05) and meropenem on day 6 (P " 0.009). Survival with the combination of polymyxin B with meropenem was significantly improved only on day 1 (P " 0.02); treatment with polymyxin B and rifampicin was no better than their single drug counterparts.
When the in vivo data for the two more resistant isolates (ME9 and IF19) were combined, several observations were noteworthy. First, the groups receiving monotherapy with the higher dose of ceftazidime/avibactam had significantly higher survival rates throughout the treatment period (P 0.006) and survival rates were consistently higher than polymyxin B therapy. Second, the survival rates in groups receiving the combinations of the lower dose of ceftazidime/avibactam with either meropenem or amikacin were significantly (P 0.0001 and P 0.02, respectively) better than single agent therapy throughout the treatment period. Finally, survival rates in the groups receiving polymyxin B with either meropenem or rifampicin were not significantly improved over single agent therapy.
Isolate KC850
Isolate KC850 had a unique repPCR pattern and was resistant to meropenem and amikacin, and had a ceftazidime/avibactam MIC of 1/4 mg/L. This isolate also had the frameshift mutation at amino acid 42 in ompK35 and possessed a Leu-Pro insertion in loop 4 and an Ala insertion in loop 5 of OmpK36. In vitro, bactericidal activity was observed for both ceftazidime/avibactam and polymyxin B as single agents (Figure 1c) ; the fixed concentrations used in the time-kill experiments were four times the MIC of each agent. As a result, similar bactericidal activity was seen with the combinations of ceftazidime/avibactam with amikacin, meropenem or polymyxin B. When concentrations of one-quarter of the MIC were used for ceftazidime/avibactam, synergistic and bactericidal activity was observed when combined with meropenem, but not with amikacin. For the polymyxin B-based studies, bactericidal activity was observed with polymyxin B with or without the addition of meropenem or rifampicin (data not shown).
In the G. mellonella model of infection, monotherapy with meropenem resulted in a higher survival rate on day 6 (P " 0.03) and with amikacin on days 3 (P " 0.05) and 6 (P " 0.03). At day 3, both low-dose (P " 0.02) and high-dose (P 0.001) therapy with Activity of agents against KPC-producing K. pneumoniae JAC ceftazidime/avibactam resulted in improved survival. Improved survival was also seen on day 6 for both the low-dose (P " 0.01) and high-dose (P 0.001) ceftazidime/avibactam treatment groups. Combining ceftazidime/avibactam with amikacin or polymyxin B did not improve survival rates (Figure 2c ). However, the combination of low-dose ceftazidime/avibactam with meropenem resulted in significantly higher survival rates than the monotherapy groups at day 6 (P " 0.02). Finally, among the polymyxin B-based combinations, survival in the group receiving polymyxin B with meropenem was significantly higher at days 1, 3 and 6 (P , 0.001) than the groups receiving either agent alone. The combination of polymyxin B plus rifampicin was not better than polymyxin B alone.
Isolate QU98
Isolate QU98 was also a unique strain and was the most susceptible of the four isolates, being susceptible to polymyxin B, ceftazidime/avibactam and amikacin, and possessing a meropenem MIC of 4 mg/L ( Table 1 ). This isolate did not have the frameshift mutation in ompK35, but had a premature stop codon at amino acid 144 in ompK36. Bactericidal activity was observed for ceftazidime/ avibactam, amikacin and the combinations of ceftazidime/avibactam with amikacin and meropenem (Figure 1d ). Polymyxin B alone was bacteriostatic and antagonism was noted when this agent was combined with ceftazidime/avibactam. Using concentrations one-quarter the MIC of ceftazidime/avibactam, synergism was observed when combined with polymyxin B, and synergistic and bactericidal killing when combined with meropenem. Finally, synergistic and bactericidal killing was observed for the combination of polymyxin B and rifampicin. In the G. mellonella model, when compared with untreated controls, significantly higher survival rates were observed at days 1, 3 and 6 in the groups receiving monotherapy with polymyxin B, meropenem, amikacin and ceftazidime/avibactam (both low and high dose; Figure 2d ). As such, high survival rates were also seen in the combination groups. Finally, the combination of meropenem or rifampicin with polymyxin B failed to improve survival over single drug therapy. The combination of polymyxin B and rifampicin performed quite poorly. Administration of rifampicin alone also resulted in higher mortality rates on day 3 (P " 0.02) compared with untreated controls, suggesting a deleterious effect of this agent against this particular isolate (data not shown).
When the in vivo data for the two more susceptible isolates (KC850 and QU98) were combined, several observations were again noted. First, the groups receiving monotherapy with the two different doses of ceftazidime/avibactam were similar. Second, the addition of meropenem, amikacin or polymyxin B to ceftazidime/avibactam did not significantly improve survival. Nath et al.
Finally, survival rates in the groups receiving polymyxin B with rifampicin were considerably worse than the groups receiving polymyxin B monotherapy throughout the treatment period (P 0.07).
Discussion
Several observations can be made regarding our results. First, the activity of ceftazidime/avibactam against KPC-possessing K. pneumoniae was quite dependent on the MIC for the isolate and the concentration of antibiotic used. For our two isolates with ceftazidime/avibactam MICs of 1/4 mg/L, using concentrations approximately four times the MIC resulted in considerable in vitro and in vivo activity, and the addition of a second agent (meropenem, amikacin or polymyxin B) generally did not enhance activity further. Therefore, monotherapy with ceftazidime/avibactam might be considered for more susceptible isolates and involving infections where drug concentrations will be adequate. However, for our two isolates with ceftazidime/avibactam MICs of 8/4 mg/L, activity was poor when concentrations around the MIC were employed in both the in vitro and in vivo models. Addition of another agent (meropenem, amikacin or polymyxin B) typically resulted in improved activity. Using higher doses of ceftazidime/avibactam in our in vivo model improved survival involving one of the two isolates. Therefore, for isolates with reduced susceptibility (MICs 4/4-8/4 mg/L) to ceftazidime/avibactam, or when concentrations of ceftazidime/avibactam at the site of infection are expected to be hovering around the MIC for the isolate, using combination therapy may be appropriate. Given the toxicities of amikacin and polymyxin B, adding meropenem to ceftazidime/ avibactam may afford the most reliable and safe regimen. Emergence of resistance has been documented when patients with infections due to KPC-producing isolates have been treated with ceftazidime/avibactam. 13 Whether the addition of a second agent to ceftazidime/avibactam can prevent this emergence remains to be seen.
For the two isolates with resistance to polymyxin B, use of this agent, even when combined with meropenem or rifampicin, resulted in poor activity. Although the addition of rifampicin to polymyxin B often resulted in synergy in the time-kill experiments, this combination was consistently ineffective in the in vivo experiments. The use of the combination of polymyxin B with rifampicin is not supported by our data.
This study is limited by the small number of strains and may not be generalized to all KPC-producing strains. Furthermore, the applicability of the larval model to human infection is unclear. Until additional clinical studies are performed, combining ceftazidime/ avibactam with another agent should be encouraged when treating serious infections due to KPC-possessing K. pneumonia when (i) there is reduced susceptibility (MICs 4/4-8/4 mg/L) to ceftazidime/avibactam or (ii) infections are deep-seated and concentrations at the site of infection may be reduced. Given the toxicities of the other agents, the combination of ceftazidime/avibactam with meropenem may afford the most reliable and safe regimen. Finally, for susceptible isolates, aminoglycosides remain a therapeutic option, although toxicities remain a concern if an extended course of therapy is anticipated.
